Objective:

2

To confirm the efficacy and safety of Ganyushu Granule (GYSG) in treating premenstrual syndrome (PMS) in patients with Gan (Liver) depression and qi stagnation syndrome (GDQSS) and determine its effective dosage.

Methods:

2

From June 2018 to March 2021

a total of 240 PMS women with GDQSS were included and randomly divided into 3 groups in a 1:1:1 ratio using central block randomization: high-dose GYSG group (

n

=78

GYSG 2 packs/time)

low-dose GYSG group (

n

=82

GYSG and its simulant 1 pack/time)

and placebo group (

n

=80

GYSG simulant 2 packs/time). Treatment with GYSG or placebo was given thrice daily and for up to 3 menstrual cycles. Primary outcomes were PMS diary (PMSD) score and premenstrual tension syndrome self-rating scale (PMTS). Secondary outcomes were Chinese medicine (CM) syndrome efficacy. PMSD

PMTS

a

nd efficacy of CM were evaluated with menstrual cycles during the treatment period. Outcome indicators were analyzed after each menstrual cycle. All analyses were performed using an intention-to-treat method

and clinical safety was assessed.

Results:

2

Of the 216 patients included in the effectiveness analysis

70

75

and 71 patients were in the high-

low-dose GYSG

and placebo groups

respectively. From the 2nd treatment cycle

the change in PMSD scores in the high- and low-dose groups was lower than that in the placebo group (

P

<

0.05). PMTS scores in the high-dose GYSG group after the 1st treatment cycle was lower than that in the placebo group (

P

<

0.05)

while after the 3rd treatment cycle

that in the low-dose group was lower than that in the placebo group (

P

<

0.05). After the 2nd treatment cycle

the high-dose GYSG group had the best CM syndrome efficacy (

P

<

0.05). No serious adverse reactions were reported.

Conclusions:

2

GYSG was safe and well-tolerated at both doses for treating PMS patients with GDQSS. High-dose GYSG might be the optimal dose for a phase Ⅲ trial. (Registration No. ChiCTR1800016595)